Compare LARK & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LARK | IXHL |
|---|---|---|
| Founded | 1885 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 134.7M |
| IPO Year | N/A | N/A |
| Metric | LARK | IXHL |
|---|---|---|
| Price | $26.32 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.1K | ★ 7.3M |
| Earning Date | 01-28-2026 | 02-13-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $64,367,999.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | ★ 12.95 | N/A |
| 52 Week Low | $21.31 | $0.08 |
| 52 Week High | $29.56 | $2.25 |
| Indicator | LARK | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 31.95 |
| Support Level | $25.92 | $0.34 |
| Resistance Level | $27.11 | $0.37 |
| Average True Range (ATR) | 0.69 | 0.02 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 61.63 | 9.25 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.